Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Korea.
Neonatology. 2012;101(3):183-91. doi: 10.1159/000329822. Epub 2011 Nov 8.
Lung lavage with diluted surfactant has emerged as an innovative treatment for meconium aspiration syndrome (MAS). However, the treatment effect has not yet been fully established.
To investigate the effects of surfactant lavage therapy for MAS by a systematic meta-analysis.
Relevant studies were identified by database searches in MEDLINE (from 1950), EMBASE (from 1980), and CENTRAL, up to June 2010, and by additional hand searches. Meta-analyses were separately conducted for randomized controlled trials (RCTs) and non-randomized controlled studies (NRSs). Risk of bias was assessed and clinical as well as statistical heterogeneities were also investigated in explaining the potential bias.
Two RCTs (87 patients) and eight NRSs (178 patients) were identified. From the results of the meta-analysis of RCTs, surfactant lavage significantly decreased death or the need for extracorporeal membrane oxygenation (RR 0.34, 95% CI 0.11, 0.99). An interventional benefit was indicated for other outcomes, although it was not statistically significant based only on the two RCTs. Results from the analysis of outcomes from NRSs are consistent with those from RCTs and demonstrated a beneficial effect, which could be considered as supporting evidence.
Lung lavage with diluted surfactant appeared to improve the clinical outcome in infants with MAS. Given that less than 100 infants were included in the two RCTs, the findings of this study may still be regarded as insufficient evidence. Further research will be needed to confirm the benefit as well as to refine the lavage technique.
肺灌洗加用表面活性物质已成为一种治疗胎粪吸入综合征(MAS)的创新疗法。然而,其治疗效果尚未得到充分证实。
通过系统评价来研究肺灌洗加用表面活性物质治疗 MAS 的效果。
通过检索 MEDLINE(1950 年以来)、EMBASE(1980 年以来)和 CENTRAL,以及附加的手工检索,确定相关研究。分别对随机对照试验(RCT)和非随机对照研究(NRS)进行荟萃分析。评估偏倚风险,并对临床和统计学异质性进行研究,以解释潜在的偏倚。
共确定了两项 RCT(87 例患者)和八项 NRS(178 例患者)。RCT 荟萃分析结果显示,肺灌洗加用表面活性物质可显著降低病死率或需要体外膜肺氧合(RR 0.34,95%CI 0.11,0.99)。虽然仅基于两项 RCT,其他结局的干预效果有提示性,但未达到统计学意义。NRS 结局分析的结果与 RCT 一致,显示出有益的效果,可作为支持证据。
用稀释的表面活性物质进行肺灌洗似乎改善了 MAS 婴儿的临床结局。鉴于两项 RCT 纳入的婴儿不足 100 例,本研究的结果仍可能被视为证据不足。需要进一步研究来证实其疗效,并完善灌洗技术。